ilomastat has been researched along with Anthrax in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bottini, M; Day, R; Desjardins, R; Fugere, M; Guiney, DG; Lebl, M; Liddington, RC; Mustelin, T; Nelson, NA; Parent, A; Pellecchia, M; Ratnikov, BI; Rega, MF; Remacle, AG; Sabet, M; Savinov, AY; Shiryaev, SA; Smith, JW; Strongin, AY; Wei, G | 1 |
| Amin, EA; De La Mora-Rey, T; Finzel, BC; Geders, TW; Hwang, DJ; Johnson, RL; Kurbanov, EK; Maize, KM; Walters, MA | 1 |
2 other study(ies) available for ilomastat and Anthrax
| Article | Year |
|---|---|
Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens.
Topics: Amino Acid Motifs; Amino Acid Sequence; Animals; Anthrax; Binding Sites; Furin; Hemagglutinin Glycoproteins, Influenza Virus; Mice; Mice, Inbred C57BL; Models, Chemical; Molecular Sequence Data; Peptides; Protein Binding; Pseudomonas; Spectrometry, Fluorescence | 2007 |
Anthrax toxin lethal factor domain 3 is highly mobile and responsive to ligand binding.
Topics: Anthrax; Antigens, Bacterial; Bacillus anthracis; Bacterial Toxins; Binding Sites; Crystallography, X-Ray; Drug Design; Humans; Ligands; Metalloendopeptidases; Models, Molecular; Peptides; Protein Conformation; Protein Structure, Tertiary; Sulfonamides | 2014 |